MYL6 and microscopic polyangiitis: This study indicated that the BVAS, especially the cutaneous, cardiovascular, and nervous system evaluation items, of anti-MYL6 antibody-positive MPA patients was lower than anti-MYL6 antibody-negative MPA patients and that the proportion of patients with remission 6 months after initiation of remission-induction therapy in anti-MYL6 antibody-positive MPA patients was significantly higher than in anti-MYL6 antibody-negative MPA patients.